With Trump’s Return, Pharma Trades Disagreeable Knowns For Uncertainty

 
• By Jessica Merrill

Drug pricing policies, M&A oversight, FDA and HHS leadership, the Biosecure Act and tariffs are among the issues pharmaceutical manufacturers will be closely watching under a second Trump Administration.

FDA and HHS leadership could be a concern for pharma when Donald Trump returns to the White House. (Shutterstock)

More from Elections

More from Legislation